Topical azelastine in perennial allergic conjunctivitis

SUMMARY Objective: Azelastine is a selective H1-receptor antagonist that inhibits histamine release and interferes with activation of several other mediators of allergic inflammation. Together with demonstrated efficacy in seasonal allergic conjunctivitis, azelastine indicated a therapeutic potentia...

Full description

Saved in:
Bibliographic Details
Published in:Current medical research and opinion 2003, Vol.19 (4), p.321-329
Main Authors: Canonica, G. W., Ciprandi, G., Petzold, U., Kolb, C., Ellers-Lenz, B., Hermann, R.
Format: Article
Language:English
Subjects:
Administration, Topical
Adolescent
Adult
Aged
Analysis of Variance
Anti-Allergic Agents - therapeutic use
Antihistamine
Azelastine
Biological and medical sciences
Conjunctivitis, Allergic - drug therapy
Conjunctivitis, Allergic - physiopathology
Double-Blind Method
Female
Histamine H1 Antagonists - therapeutic use
Humans
Levocabastine
Male
Medical sciences
Middle Aged
Ophthalmic Solutions - therapeutic use
Perennial allergic conjunctivitis
Phthalazines - therapeutic use
Piperidines - therapeutic use
Rhinitis, Allergic, Perennial - drug therapy
Rhinitis, Allergic, Perennial - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SUMMARY Objective: Azelastine is a selective H1-receptor antagonist that inhibits histamine release and interferes with activation of several other mediators of allergic inflammation. Together with demonstrated efficacy in seasonal allergic conjunctivitis, azelastine indicated a therapeutic potential for perennial allergic conjunctivitis (PAC). The present study aimed to evaluate azelastine eye drops in patients with PAC compared to placebo. Research design and methods: A multinational trial in 22 centres randomised 139 patients to twice-daily treatment for 6 weeks with masked 0.05% azelastine eye drops, matching masked placebo, or open-label levocabastine. Randomisation required a sum itching and conjunctival redness score of at least 3 (0-6 scale) after 1 week of placebo. The change in sum score was evaluated during treatment. Results: Azelastine significantly improved itching and conjunctival redness compared to placebo (p 
ISSN:0300-7995
1473-4877
DOI:10.1185/030079903125001794